Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-37807, 0.1% · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-37807 | EXPERIMENTAL | AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| Timolol | ACTIVE_COMPARATOR | Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| AL-37807 vehicle | PLACEBO_COMPARATOR | AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks |
| AL-37807 Suspension | EXPERIMENTAL | - |
| Xalatan | ACTIVE_COMPARATOR | - |
| Timolol Maleate | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AL-37807 ophthalmic suspension, 0.1% | DRUG | - |
| Timolol gel forming solution, 0.5% | DRUG | - |
| AL-37807 ophthalmic solution vehicle | OTHER | - |
| Latanoprost ophthalmic solution | DRUG | - |
| AL-37807 | DRUG | - |
| AL-37807 Ophthalmic Suspension, 1.0% | DRUG | One drop in the study eye(s) once daily for 28 days |
| Latanoprost, 0.005% (Xalatan) | DRUG | One drop in the study eye(s) once daily for 28 days |
| AL-37807 Vehicle | OTHER | One drop in the study eye(s) once daily for 28 days |
| Timolol Maleate Ophthalmic Gel Forming Solution, 0.5% | DRUG | One drop in the study eye(s) once daily for 28 days |
Inclusion Criteria: * Open-angle glaucoma * Ocular hypertension * Must have been on Xalatan for at least 3 months * VA not worse than 0.60 * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Age related * Other protocol-defined exclusion criteria may apply
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
AL-37807 is an investigational small molecule being developed for the treatment of open-angle glaucoma and ocular hypertension. It is formulated as a 0.1% ophthalmic suspension and has been studied in Phase 2 clinical trials in the United States.
AL-37807 is being developed by Alcon Inc. (NYSE: ALC), a pharmaceutical company focused on eye care. The drug is in Phase 2 clinical development for open-angle glaucoma and ocular hypertension.
AL-37807 is in Phase 2 clinical development. It has completed three Phase 2 trials, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
AL-37807 has been studied in three completed Phase 2 trials: NCT00287521 (87 participants), NCT00372931 (120 participants), and NCT00620256 (129 participants). All trials were conducted in the United States and enrolled adults with open-angle glaucoma or ocular hypertension.
Yes, AL-37807 has been evaluated in randomized, double-blind, placebo-controlled Phase 2 trials. The three completed studies enrolled a total of 336 participants and compared the drug against placebo in patients with open-angle glaucoma or ocular hypertension.